The Mobi-C cervical disc is one of the most widely used cervical discs in the world. First implanted in Orleans, France in November 2004, Mobi-C has been implanted in more than 17,000 spinal levels in 25 countries.
A total of 599 patients were involved in the Mobi-C U.S. clinical trial, which represents the largest concurrent clinical trial ever conducted for cervical disc replacement. Mobi-C received FDA approval in August of 2013, making it the first cervical disc with both one and two-level indications.
Dr. Regan performed a cervical artificial disc replacement surgery to relieve pain & allow him to retain neck mobility. Click here to read about John's successful return to active lifestyle without pain after Dr. John Regan performed the Mobi-C artificial disc replacement.
Mobi-C contains patented Mobile Core Technology™ that allows the polyethylene core to slide and rotate inside the disc for self-adjustment to the cervical spine movements. This means that Mobi-C can react to the normal motion in the cervical spine.
Mobi-C provides bone sparing fixation without chisel cuts into the small vertebral bodies of the cervical spine, making it safe for implantation at two levels.
In the one-level study, Mobi-C demonstrated non-inferiority to ACDF as reflected in the primary composite endpoint. In the two-level study Mobi-C demonstrated SUPERIORITY to ACDF in the primary composite endpoint. Key results from the two-level study include:
Overall trial success was 69.7% for Mobi-C and 37.4% for fusion, which represents statistical superiority (p< 0.0001).
The rate of secondary surgeries at the operated level for Mobi-C was 3.1% versus 11.4% for fusion.
The percentage of subjects who demonstrated adjacent segment degeneration (determined by x-ray) was:
Educational and video content provided by Mobi-C
As a free community service, Spine Group Beverly Hills mails out Home Remedy Books on a limited basis to residents in Southern California.